Ardelyx, Inc. 8-K Filing
Ticker: ARDX · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1437402
| Field | Detail |
|---|---|
| Company | Ardelyx, Inc. (ARDX) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ardelyx, Inc. (ticker: ARDX) to the SEC on Dec 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat).
How long is this filing?
Ardelyx, Inc.'s 8-K filing is 3 pages with approximately 921 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 921 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-12-17 17:02:37
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat
Filing Documents
- ardx-20251217.htm (8-K) — 28KB
- ardx-20251217_g1.jpg (GRAPHIC) — 3KB
- 0001437402-25-000021.txt ( ) — 151KB
- ardx-20251217.xsd (EX-101.SCH) — 2KB
- ardx-20251217_lab.xml (EX-101.LAB) — 22KB
- ardx-20251217_pre.xml (EX-101.PRE) — 13KB
- ardx-20251217_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Edward Conner, M.D. has notified the Company of his decision to resign as Chief Medical Officer of the Company, effective December 31, 2025. Dr. Conner resigned for personal reasons, and his resignation is not a result of any disagreement with the Company. Dr. Laura Williams, the Company's Chief Patient Officer and former Chief Medical Officer, will serve as interim Chief Medical Officer, assuming key responsibilities, including strategic guidance for the Company's clinical development programs, until a new Chief Medical Officer is hired.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 ARDELYX, INC. By: /s/ Susan Hohenleitner Susan Hohenleitner Chief Financial Officer